Overview


According to FutureWise analysis the market for Nucleic Acid Based Drugs is expected to reach US$ 0.16 billion by 2031 at a CAGR of 20.00%.

Nucleic acid-based drugs are target therapies that are based on nucleic acids or nearly identical chemical compounds. These drugs have the ability to target genetic disorders and prevent disease-causing proteins from being produced. Oligonucleotides, which are synthesised chemically, and small molecules are the most active elements in nucleic acids. Nucleic acids are commonly thought of as drug transporters, but they can also trigger unwanted biological reactions like immune system activation and blood clotting pathway expansion. As a result, the basic motive for their growing use in the market is the benefits of nucleic acid-based pharmaceuticals in prospective drug delivery systems for controlled drug releases. Nucleic acid drugs are being used to develop new therapeutic strategies. They offer promise in treating human diseases such as cancer, viral infections, and genetic abnormalities due to their unique features that allow them to address undruggable areas utilising traditional small molecule or protein/antibody-based biologics. Nucleic acid drugs work by influencing the biological processes of cells using nucleotide sequence information. These drugs work by controlling genes, particularly those with complementary sequences, or by expressing themselves in cells. Multi-genetic disorders are becoming more prevalent. Nucleic acid pharmaceuticals are next-generation medications that took a long time and a lot of effort to develop. It's been 40 years since the discovery of nucleic acid as a measure to prevent virus replication. Increasing healthcare infrastructure investment are some of the factors contributing to growth in these Market. The expiration of copyrighted medication and the release of generic versions of drugs, on the other hand, will slow the market's growth rate. The market for nucleic acid-based pharmaceuticals will be challenged by a lack of healthcare infrastructure in developing economies and high drug costs. Furthermore, the market's growth pace will be slowed by side effects associated with nucleic acid-based drugs.

FutureWise Market Research has instantiated a report that provides an intricate analysis of Nucleic Acid Based Drugs Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market.

According to the research study conducted by FutureWise research analysts, the Nucleic Acid Based Drugs Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.

  • Eli Lilly and Company
  • Wave Life Sciences Ltd.
  • Copernicus Therapeutics Inc.
  • Imugene
  • PYC Therapeutics
  • Protagonist Therapeutics Inc.
  • Benitec Biopharma
  • Egen, Inc.
  • Biomedica Medizinprodukte GmbH
  • Transgene
  • Arrowhead Pharmaceuticals, Inc.
  • Ionis Pharmaceuticals
  • Alnylam Pharmaceuticals, Inc.
  • Moderna, Inc.
  • Gotham Therapeutics
  • Sumitomo Chemical Co., Ltd.

(Note: The list of the major players will be updated with the latest market scenario and trends)

By Category

  • Antisense
  • SiRNA
  • MiRNA
  • Aptamer
  • Decoy
  • CpG-oilgo

By Structure

  • Single Stranded DNA/RNA
  • Double Stranded DNA
  • Single-Stranded DNA
  • Others

By Target

  • Transcriptor Factor
  • TLR9-Receptor
  • Protein

By Mechanism

  • Inhibits the Physiological Effect
  • Adjuvant
  • Inhibits Transcription
  • Others

By End-Users

  • Hospitals
  • Specialty Clinics
  • Homecare
  • Others

By Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
  • Others

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants

  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth

  • To provide with an exhaustive analysis on the Nucleic Acid Based Drugs Market By Category, By Structure, By Target, By Mechanism, By End-Users, By Distribution Channel and By Region.
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  • To evaluate and forecast micro-markets and the overall market
  • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  • To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions

  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

 

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1. Years Considered for the Study
         3.2. Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Methodology
    •   1. Research Data
         1.1. Secondary Data
          1.1.1. Key Data from Secondary Sources
         1.2. Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Nucleic Acid Based Drugs Market Variables, Trends and Scope
    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Technology Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Nucleic Acid Based Drugs Market Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   Nucleic Acid Based Drugs Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Technology Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Technology Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Nucleic Acid Based Drugs Market, By Category Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Antisense
        2. SiRNA
        3. MiRNA
        4. Aptamer
        5. Decoy
        6. CpG-oilgo

  • 8.   Nucleic Acid Based Drugs Market, By Structure Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Single Stranded DNA/RNA
        2. Double Stranded DNA
        3. Single-Stranded DNA
        4. Others

  • 9.   Nucleic Acid Based Drugs Market, By Target Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Transcriptor Factor
        2. TLR9-Receptor
        3. Protein

  • 10.   Nucleic Acid Based Drugs Market, By Mechanism Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Inhibits the Physiological Effect
        2. Adjuvant
        3. Inhibits Transcription
        4. Others

  • 11.   Nucleic Acid Based Drugs Market, By End-Users Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Hospitals
        2. Specialty Clinics
        3. Homecare
        4. Others

  • 12.   Nucleic Acid Based Drugs Market, By Distribution Channel Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Hospital Pharmacy
        2. Retail Pharmacy
        3. Online Pharmacy
        4. Others

  • 13.   North America Nucleic Acid Based Drugs Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2023-2031

  • 14.   Latin America Nucleic Acid Based Drugs Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2023-2031

  • 15.   Europe Nucleic Acid Based Drugs Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2023-2031

  • 16.   Asia Pacific Nucleic Acid Based Drugs Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Japan
         2.2. China
         2.3. India
         2.4. Australia and New Zealand
         2.5. ASEAN
         2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2023-2031

  • 17.   Middle East and Africa Nucleic Acid Based Drugs Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. GCC
         2.2. Israel
         2.3. South Africa
         2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2023-2031

  • 18.   Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix
  • 19.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
    •   1. Eli Lilly and Company
         1.1. Company Overview
         1.2. Product Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. Wave Life Sciences Ltd.
         2.1. Company Overview
         2.2. Product Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. Copernicus Therapeutics Inc.
         3.1. Company Overview
         3.2. Product Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. Imugene
         4.1. Company Overview
         4.2. Product Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. PYC Therapeutics
         5.1. Company Overview
         5.2. Product Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
        6. Protagonist Therapeutics Inc.
         6.1. Company Overview
         6.2. Product Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview
        7. Benitec Biopharma
         7.1. Company Overview
         7.2. Product Portfolio
         7.3. SWOT Analysis
         7.4. Financial Overview
         7.5. Strategic Overview
        8. Egen, Inc.
         8.1. Company Overview
         8.2. Product Portfolio
         8.3. SWOT Analysis
         8.4. Financial Overview
         8.5. Strategic Overview
        9. Biomedica Medizinprodukte GmbH
         9.1. Company Overview
         9.2. Product Portfolio
         9.3. SWOT Analysis
         9.4. Financial Overview
         9.5. Strategic Overview
        10. Transgene
         10.1. Company Overview
         10.2. Product Portfolio
         10.3. SWOT Analysis
         10.4. Financial Overview
         10.5. Strategic Overview
         11. Arrowhead Pharmaceuticals, Inc.
          11.1. Company Overview
          11.2. Product Portfolio
          11.3. SWOT Analysis
          11.4. Financial Overview
          11.5. Strategic Overview
         12. Ionis Pharmaceuticals
          12.1. Company Overview
          12.2. Product Portfolio
          12.3. SWOT Analysis
          12.4. Financial Overview
          12.5. Strategic Overview
        13. Alnylam Pharmaceuticals, Inc.
          13.1. Company Overview
          13.2. Product Portfolio
          13.3. SWOT Analysis
          13.4. Financial Overview
          13.5. Strategic Overview
        14. Moderna, Inc.
          14.1. Company Overview
          14.2. Product Portfolio
          14.3. SWOT Analysis
          14.4. Financial Overview
          14.5. Strategic Overview
         15. Gotham Therapeutics
          15.1. Company Overview
          15.2. Product Portfolio
          15.3. SWOT Analysis
          15.4. Financial Overview
          15.5. Strategic Overview
         16. Sumitomo Chemical Co. Ltd.
          16.1. Company Overview
          16.2. Product Portfolio
          16.3. SWOT Analysis
          16.4. Financial Overview
          16.5. Strategic Overview

  • 20.   Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the healthcare regulations initiated by administrations
        5. The overall economic slowdown of the developing and developed nations
  • 21.   FutureWise SME Key Takeaway Points for Client
Partner

Our Clients